What question did this study set out to answer?

To provide evidence-based, expert consensus recommendations for investigating and managing persistent thrombocytosis in patients lacking canonical JAK2, CALR, or MPL driver mutations.

December 4, 2025British Journal of HaematologyOpen Access

Investigation and management of thrombocytosis without JAK2 , CALR or MPL mutations: A British Society for Haematology Guideline

View Full Paper

Ask AI

Bookmark

Authors

AGAnna L. GodfreyCambridge University Hospitals NHS Foundation Trust AKAlesia KhanLeeds Teaching Hospitals NHS Trust AMAndrew McGregorNewcastle upon Tyne Hospitals NHS Foundation Trust

Discussion

Member takes

Implication

Clinical guideline provides diagnostic and management frameworks for patients with driver-negative thrombocytosis, highlighting tailored bone marrow and genomic evaluations.

Key Points

To provide evidence-based, expert consensus recommendations for investigating and managing persistent thrombocytosis in patients lacking canonical JAK2, CALR, or MPL driver mutations.
Formulated according to the British Society for Haematology (BSH) guideline development process using GRADE methodology to evaluate evidence levels and recommendation strength.
Synthesized literature reviews, expert panel evaluations, and multidisciplinary consultations covering diagnostic algorithms, histological evaluations, and genomic testing paradigms.
Secondary causes account for over 80% of thrombocytosis cases and must be systematically ruled out using inflammatory markers, iron studies, and clinical imaging.
Triple-negative essential thrombocythaemia cases, most common in young females, show lower thrombosis rates and reduced risk of myelofibrotic transformation compared to driver-positive cases.
Selective bone marrow biopsy and next-generation sequencing myeloid panels are advised based on platelet thresholds, age, and systemic features to avoid over-investigating benign or clonal haematopoiesis presentations.

Cite This Study

Godfrey et al. (2025) studied this question.

synapsesocial.com/papers/6a10c022ed67694fb09f6477 https://doi.org/10.1111/bjh.70260

View Full Paper

Ask AI

Bookmark

Implication

Clinical guideline provides diagnostic and management frameworks for patients with driver-negative thrombocytosis, highlighting tailored bone marrow and genomic evaluations.

Investigation and management of thrombocytosis without JAK2 , CALR or MPL mutations: A British Society for Haematology Guideline

Discussion

Member takes

Implication

Key Points

Cite This Study

Investigation and management of thrombocytosis without JAK2 , CALR or MPL mutations: A British Society for Haematology Guideline

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider